How to Get Vyleesi in Georgia

Georgia Telehealth Prescribing for Vyleesi

Georgia law permits licensed prescribers to evaluate and prescribe bremelanotide via telehealth without requiring an in-person visit first. This means a premenopausal woman in any Georgia county can consult a physician, nurse practitioner, or physician assistant through a video or audio-visual platform and receive a valid prescription the same day.

Georgia's telemedicine statute (O.C.G.A. § 33-24-56.4) requires that the prescriber hold an active Georgia medical license or a compact-state license recognized by Georgia. The prescriber must establish a provider-patient relationship during the synchronous visit, which includes reviewing medical history, current medications, blood pressure readings, and relevant symptoms consistent with hypoactive sexual desire disorder (HSDD). The FDA label for bremelanotide specifies that the drug is contraindicated in patients with uncontrolled hypertension or cardiovascular disease, so blood pressure documentation is a baseline requirement [1].

Telehealth platforms specializing in women's sexual health can typically schedule Georgia patients within 48 hours. The consultation itself runs 15 to 30 minutes, depending on the complexity of the patient's history.

Who Can Prescribe Vyleesi in Georgia

Any Georgia-licensed MD, DO, NP, or PA with prescriptive authority can write a bremelanotide prescription. There is no special certification, DEA schedule restriction, or REMS program gating access.

Nurse practitioners in Georgia operate under a protocol agreement with a collaborating physician, but this does not prevent them from prescribing Vyleesi independently once the agreement is in place. PAs in Georgia prescribe under physician delegation. Both can initiate bremelanotide therapy as long as the indication aligns with their scope. Board-certified OB/GYNs and sexual medicine specialists are the most common prescribers, though primary care providers regularly initiate therapy when the diagnosis is straightforward.

The diagnostic criteria for HSDD follow the DSM-5 definition: persistently deficient or absent sexual desire causing marked personal distress, not attributable to another medical condition, psychiatric disorder, relationship factor, or substance use [2]. The Endocrine Society's clinical practice guidelines recommend structured screening questionnaires such as the Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI) to standardize diagnosis [3].

Labs and Assessments Before Prescribing

The pre-prescription workup for Vyleesi in Georgia is not extensive. No mandatory lab panel is legally required by the state. Clinical best practice, however, calls for specific baseline evaluations.

Blood pressure measurement is the single most important pre-treatment data point. The FDA label contraindicates bremelanotide in uncontrolled hypertension because the drug produces transient BP elevations of approximately 6 mmHg systolic and 3 mmHg diastolic after injection [1]. In the RECONNECT trials (N=1,247), these increases resolved within 12 hours in most subjects [4].

Beyond blood pressure, clinicians typically order:

• Thyroid panel (TSH, free T4) to exclude hypothyroidism as a cause of low desire
• Complete metabolic panel for baseline hepatic and renal function
• Prolactin level to rule out hyperprolactinemia
• Testosterone (total and free) in cases where androgen deficiency is suspected

These labs can be completed at any Quest, Labcorp, or hospital-affiliated draw station across Georgia. Results are usually available within 2 to 3 business days. Some telehealth platforms partner directly with lab networks to send requisitions electronically, eliminating the need for faxed orders.

Pharmacy Access and 503A Compounding in Georgia

Once prescribed, Vyleesi can be dispensed through two primary channels in Georgia: specialty pharmacies carrying the brand-name product and 503A compounding pharmacies licensed by the Georgia Board of Pharmacy.

Brand-name Vyleesi ships as a pre-filled, single-dose autoinjector (1.75 mg/0.3 mL). Specialty pharmacies like Optum Specialty, CVS Specialty, and Alto ship directly to Georgia addresses. The branded product's wholesale acquisition cost sits around $900 per month for 8 autoinjectors. Without insurance coverage, patient assistance programs from the manufacturer may reduce out-of-pocket cost.

503A compounding pharmacies in Georgia can prepare bremelanotide in subcutaneous injection form when a patient-specific prescription exists. Georgia's Board of Pharmacy licenses these facilities under O.C.G.A. § 26-4-110, and they must comply with USP 797 sterile compounding standards. Compounded bremelanotide typically costs 40% to 70% less than the branded autoinjector. Patients receive multi-dose vials with insulin syringes rather than pre-filled pens.

Georgia-based 503A pharmacies can ship within the state and, in many cases, to other states where their license permits. Turnaround from prescription receipt to shipping averages 3 to 5 business days for sterile compounds.

Insurance Coverage and Prior Authorization in Georgia

Georgia Medicaid does not cover Vyleesi for HSDD. The state Medicaid formulary restricts bremelanotide-related coverage to type 2 diabetes indications only, which reflects an older formulary classification error that has not been updated since the drug's 2019 FDA approval for HSDD.

Private insurers in Georgia vary widely. Some commercial plans (Anthem Blue Cross Blue Shield of Georgia, Aetna, UnitedHealthcare) may cover Vyleesi under specialty pharmacy benefits with prior authorization. The prior authorization process typically requires:

• Documented HSDD diagnosis with DSM-5 criteria
• Evidence that the condition is not caused by a co-existing medical or psychiatric condition
• Trial and failure (or contraindication) of at least one alternative therapy
• Prescriber attestation that the patient is premenopausal
• Blood pressure documentation within the past 90 days

Turnaround on prior authorization decisions ranges from 48 hours to 14 calendar days under Georgia insurance regulations. If denied, patients can appeal through their plan's internal review process or file a complaint with the Georgia Office of Insurance and Safety Fire Commissioner.

For patients without coverage, cash-pay pricing through compounding pharmacies or manufacturer discount programs remains the most accessible pathway. GoodRx and similar aggregators sometimes list bremelanotide, though availability fluctuates.

Timeline: Prescription to First Dose in Georgia

The total elapsed time from initial telehealth consultation to receiving Vyleesi at a Georgia address follows a predictable sequence.

Day 1 to 2: Telehealth consultation scheduled and completed. Prescription sent electronically to the patient's pharmacy of choice. Day 2 to 4: Pharmacy verification, insurance check (if applicable), or compounding initiated. Day 5 to 10: Medication shipped via cold-chain or standard overnight courier and delivered to the patient's home.

For patients using a 503A compounding pharmacy, sterile preparation adds 1 to 3 days compared to dispensing a pre-made branded product. Patients transferring an existing Vyleesi prescription from another state to a Georgia pharmacy can expect transfer processing within 24 to 48 hours, as Georgia permits inter-state prescription transfers for non-controlled substances.

Clinical Efficacy: What the RECONNECT Data Show

The FDA approved bremelanotide based on the RECONNECT program, two replicate phase 3 trials enrolling 1,247 premenopausal women with HSDD [4]. At 24 weeks, bremelanotide-treated patients experienced a statistically significant increase in desire (measured by the Female Sexual Function Index desire domain) and a reduction in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) compared to placebo.

Specifically, the co-primary endpoint of FSFI desire domain score improved by 0.5 points over placebo (P<0.001), and FSDS-DAO score decreased by 0.7 points versus placebo (P<0.001) [4]. Dr. Sheryl Kingsberg, a principal investigator on the RECONNECT trials and professor of reproductive biology at Case Western Reserve University, stated: "Bremelanotide addresses the neurobiological underpinnings of desire in a way that is distinct from any other approved therapy for HSDD" [4].

The most common adverse events were nausea (40% vs. 1% placebo), flushing (20%), and injection site reactions (13%). Nausea was predominantly mild-to-moderate, occurred within the first few doses, and diminished with continued use in most patients [1].

The American College of Obstetricians and Gynecologists (ACOG) recognizes bremelanotide as a treatment option for HSDD, noting that pharmacologic therapy should be considered after addressing modifiable contributing factors [5].

Bremelanotide vs. Flibanserin: Georgia Availability Comparison

Georgia patients diagnosed with HSDD have two FDA-approved pharmacologic options: bremelanotide (Vyleesi) and flibanserin (Addyi). The drugs differ in mechanism, dosing, and practical access.

Flibanserin is a daily oral pill targeting serotonin receptors. It requires a REMS certification for prescribers and pharmacies, which narrows the pool of Georgia providers who can prescribe it. Bremelanotide has no REMS requirement. Any licensed prescriber can write for it immediately.

Bremelanotide's as-needed dosing offers a practical advantage for patients who do not want daily medication. The RECONNECT trials showed efficacy with a median use of 2 to 3 doses per month [4], meaning patients self-select when to use the drug rather than committing to continuous daily therapy.

From a cost perspective in Georgia, flibanserin generic (since 2023) runs approximately $50 to $150 per month at retail pharmacies, while branded Vyleesi sits near $900 without assistance. Compounded bremelanotide through Georgia 503A pharmacies narrows this gap substantially, with typical pricing in the $200 to $400 range for a 30-day supply at standard utilization.

Safety Monitoring and Follow-Up for Georgia Patients

After initiating bremelanotide, follow-up in Georgia can continue entirely via telehealth. The standard clinical cadence includes a check-in at 4 to 6 weeks post-initiation, then every 3 to 6 months for ongoing prescriptions.

Monitoring priorities include blood pressure (patients should report any readings above 140/90), nausea management (anti-emetic pre-treatment with ondansetron 4 mg can be prescribed concurrently), and treatment satisfaction assessment using validated instruments like the FSFI.

The FDA label advises against use in patients with cardiovascular disease and recommends caution in those with hepatic impairment [1]. Georgia prescribers should document cardiovascular risk assessment at baseline and at annual intervals. The CDC's heart disease data for Georgia indicates the state has above-average cardiovascular mortality, making this screening step particularly relevant for the Georgia patient population [6].

Patients should discontinue bremelanotide and contact their provider if they experience persistent hypertension, severe nausea unresponsive to anti-emetics, or skin hyperpigmentation (reported in <2% of trial participants with prolonged use) [1].